Hepatit c tedavisindeki başarı direkt etkili oral antivirallerle %90’ları aşmaktadır. Geri ödeme kapsamındaki ilaçlar ülkeden ülkeye değişiklik göstermektedir. Ülkemizde iki farklı kombinasyon (sofosbuvir-ledipasvir ve ombitasvir-paritaprevir- ritonavir- dasabuvir) Haziran 2016’dan itibaren geri ödeme kapsamına alındı. Bununla birlikte bu kombinasyonlarla ilgili düzenlemeler kronik hepatit C tedavisinde yeni şartlar ve sınırlamalar getirdi. Bu derlemede ülkemizdeki hepatit c tedavi şemaları ve geri ödeme şartları eski ve yeni kurallarıyla gözden geçirilmiştir.
Tosun S . Viral hepatitlerin ülkemizdeki değişen epidemiyolojisi. ANKEM Derg 2013;27(Ek 2):128-134.
Chen SL. The Natural History of Hepatitis C Virus (HCV) Infection. International Journal of Medical Sciences Int J Med Sci 2006;3(2):47-52.
Sarasin-Filipowicz M. Interferon therapy of hepatitis C: molecular insights
into success and failure. Swiss Med Wkly. 2010 Jan 9;140(1-2):3-11.
American Association for the study of liver diseases (AASLD) and Infectious Diseases Society of America (IDSA). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C http://www.hcvguidelines.org (Erişim tarihi: 22.06.2016).
Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors
affecting efficacy. World J Gastroenterol. 2013 Dec 21;19(47):8963-73.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889-98.
Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594–603.
Holmes JA, Thompson AJ. Interferon-free combination therapies fort he treatment of hepatitis C: current insights. Hepat Med. 2015 Nov 2;7:51-70.
Year 2016,
Volume: 1 Issue: 2, 23 - 29, 28.06.2016
Tosun S . Viral hepatitlerin ülkemizdeki değişen epidemiyolojisi. ANKEM Derg 2013;27(Ek 2):128-134.
Chen SL. The Natural History of Hepatitis C Virus (HCV) Infection. International Journal of Medical Sciences Int J Med Sci 2006;3(2):47-52.
Sarasin-Filipowicz M. Interferon therapy of hepatitis C: molecular insights
into success and failure. Swiss Med Wkly. 2010 Jan 9;140(1-2):3-11.
American Association for the study of liver diseases (AASLD) and Infectious Diseases Society of America (IDSA). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C http://www.hcvguidelines.org (Erişim tarihi: 22.06.2016).
Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors
affecting efficacy. World J Gastroenterol. 2013 Dec 21;19(47):8963-73.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889-98.
Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594–603.
Holmes JA, Thompson AJ. Interferon-free combination therapies fort he treatment of hepatitis C: current insights. Hepat Med. 2015 Nov 2;7:51-70.